Recent findings have demonstrated the role of IL-37 in pancreatic cancers, in which the pancreatic epithelial cells could undergo sustained inflammation-related adaptive response even after inflammation has subsided, accompanied with activated KRAS oncogene to promote tumor development (114). This evidence concerns the gene IL37 and neoplasm.